Flavia Salvi

4.3k total citations
50 papers, 1.2k citations indexed

About

Flavia Salvi is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology. According to data from OpenAlex, Flavia Salvi has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pathology and Forensic Medicine, 16 papers in Genetics and 15 papers in Hematology. Recurrent topics in Flavia Salvi's work include Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Acute Myeloid Leukemia Research (10 papers). Flavia Salvi is often cited by papers focused on Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Acute Myeloid Leukemia Research (10 papers). Flavia Salvi collaborates with scholars based in Italy, Ukraine and United States. Flavia Salvi's co-authors include Umberto Vitolo, Luigi Rigacci, Annalisa Chiappella, Alessandro Levis, Maria Giuseppina Cabras, Benedetta Puccini, Caterina Stelitano, Pier Luigi Zinzani, Ercole Brusamolino and Barbara Botto and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Flavia Salvi

48 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Flavia Salvi Italy 18 948 477 425 257 203 50 1.2k
Anton Kruger United Kingdom 13 918 1.0× 512 1.1× 359 0.8× 287 1.1× 239 1.2× 26 1.2k
Igor Aurer Croatia 20 531 0.6× 449 0.9× 159 0.4× 223 0.9× 187 0.9× 88 950
Biljana Mihaljević Serbia 15 687 0.7× 417 0.9× 164 0.4× 289 1.1× 115 0.6× 103 1.1k
Lorella Orsucci Italy 15 713 0.8× 356 0.7× 243 0.6× 441 1.7× 82 0.4× 45 892
Michel Blanc France 14 757 0.8× 386 0.8× 427 1.0× 371 1.4× 127 0.6× 35 1.0k
Chiara Broglia Italy 13 396 0.4× 248 0.5× 118 0.3× 184 0.7× 147 0.7× 20 662
Allison Crosby‐Thompson United States 6 675 0.7× 393 0.8× 239 0.6× 181 0.7× 153 0.8× 11 891
Christina Balser Germany 11 1.3k 1.4× 903 1.9× 219 0.5× 825 3.2× 128 0.6× 18 1.6k
Viola Poeschel Germany 13 707 0.7× 459 1.0× 236 0.6× 269 1.0× 105 0.5× 39 872
Alejandra Talavera Mexico 16 555 0.6× 503 1.1× 155 0.4× 140 0.5× 116 0.6× 50 867

Countries citing papers authored by Flavia Salvi

Since Specialization
Citations

This map shows the geographic impact of Flavia Salvi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavia Salvi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavia Salvi more than expected).

Fields of papers citing papers by Flavia Salvi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flavia Salvi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavia Salvi. The network helps show where Flavia Salvi may publish in the future.

Co-authorship network of co-authors of Flavia Salvi

This figure shows the co-authorship network connecting the top 25 collaborators of Flavia Salvi. A scholar is included among the top collaborators of Flavia Salvi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flavia Salvi. Flavia Salvi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rigacci, Luigi, Benedetta Puccini, Alessandro Broccoli, et al.. (2019). Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. Annals of Hematology. 99(2). 283–291. 3 indexed citations
2.
Merli, Francesco, Federica Cavallo, Flavia Salvi, et al.. (2019). Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. Journal of Geriatric Oncology. 11(1). 37–40. 15 indexed citations
3.
Tesio, Luigi, et al.. (2018). Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial. Journal of Vascular Surgery Venous and Lymphatic Disorders. 6(3). 419–419. 8 indexed citations
4.
5.
Velardi, Andrea, Anja van Biezen, Loredana Ruggeri, et al.. (2016). Mother donors improve outcomes after HLA haploidentical T cell-depleted hematopoietic transplantation: A Retrospective Study by the Cell Therapy and Immunobiology Working Party of the EBMT. Bone Marrow Transplantation. 51. 2 indexed citations
6.
Pellegrini, Cinzia, Anna Dodero, Annalisa Chiappella, et al.. (2016). A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Journal of Hematology & Oncology. 9(1). 38–38. 36 indexed citations
7.
8.
Efficace, Fabio, Valeria Santini, Giorgio La Nasa, et al.. (2014). Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ Supportive & Palliative Care. 6(1). 80–88. 14 indexed citations
9.
10.
Corradini, Paolo, Umberto Vitolo, Alessandro Rambaldi, et al.. (2014). Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 28(9). 1885–1891. 62 indexed citations
11.
Luminari, Stefano, Maria Goldaniga, Marina Cesaretti, et al.. (2013). Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). Blood. 122(21). 3049–3049. 2 indexed citations
12.
Galimberti, Sara, Francesca Guerrini, Flavia Salvi, et al.. (2012). Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Journal of Hematology & Oncology. 5(1). 53–53. 9 indexed citations
13.
Latagliata, Roberto, Massimo Breccia, Paola Fazi, et al.. (2011). GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long‐term results and prognostic factors. British Journal of Haematology. 154(5). 564–568. 14 indexed citations
14.
Salvi, Flavia, Anna Baraldi, Daniela Pietrasanta, et al.. (2011). Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leukemia Research. 35(8). 991–997. 34 indexed citations
15.
16.
Zaja, Francesco, Stefania De Luca, Umberto Vitolo, et al.. (2011). Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica. 97(3). 416–422. 52 indexed citations
17.
18.
Rigacci, Luigi, Umberto Vitolo, Luca Nassi, et al.. (2007). Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Annals of Hematology. 86(12). 897–903. 69 indexed citations
19.
Levis, Alessandro, Alessandro Anselmo, Alberto Ambrosetti, et al.. (2003). VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Annals of Oncology. 15(1). 123–128. 51 indexed citations
20.
Freilone, Roberto, Barbara Botto, Umberto Vitolo, et al.. (1996). Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma. Annals of Oncology. 7(9). 919–924. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anton Kruger Breakdown of academic impact, for papers by Igor Aurer Breakdown of academic impact, for papers by Biljana Mihaljević Breakdown of academic impact, for papers by Lorella Orsucci Breakdown of academic impact, for papers by Michel Blanc Breakdown of academic impact, for papers by Chiara Broglia Breakdown of academic impact, for papers by Allison Crosby‐Thompson Breakdown of academic impact, for papers by Christina Balser Breakdown of academic impact, for papers by Viola Poeschel Breakdown of academic impact, for papers by Alejandra Talavera
Rankless by CCL
2026